BIOLASE, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Concentrations

Concentrations

9 Months Ended

Sep. 30, 2016

Risks And Uncertainties [Abstract]

Concentrations

NOTE 10—CONCENTRATIONS

Revenue from the Company’s products for the three and nine months ended September 30, 2016 and 2015 are as follows:

	Three Months Ended						Nine Months Ended
	September 30,						September 30,
	2016			2015			2016			2015
Laser systems		71.9	%		65.3	%		68.7	%		65.2	%
Imaging systems		2.6	%		6.4	%		4.5	%		4.7	%
Consumables and other		12.4	%		13.1	%		13.5	%		15.5	%
Services		12.9	%		14.9	%		13.0	%		14.1	%
License fees and royalties		0.2	%		0.3	%		0.3	%		0.5	%
Total revenue		100.0	%		100.0	%		100.0	%		100.0	%

No individual customer represented more than 10% of the Company’s revenue for the three and nine months ended September 30, 2016 or 2015.

The Company maintains its cash and cash equivalent accounts with established commercial banks. Such cash deposits periodically exceed the Federal Deposit Insurance Corporation insured limit.

No individual customer represented more than 10% of the Company’s accounts receivable at September 30, 2016 or December 31, 2015.

The Company currently purchases certain key components of its products from single suppliers. Although there are a limited number of manufacturers of these key components, management believes that other suppliers could provide similar key components on comparable terms. A change in suppliers, however, could cause delays in manufacturing and a possible loss of sales, which could adversely affect the Company’s business, results of operations, and financial condition.